Velpatasvir
Velpatasvir is a pan-genotypic NS5A inhibitor that blocks the nonstructural protein 5A of hepatitis C virus (HCV), which is essential for viral RNA replication and virion assembly. It is used in combination with sofosbuvir (Epclusa) or sofosbuvir and voxilaprevir (Vosevi) for the treatment of chronic HCV infection across all six major genotypes. Its pan-genotypic activity simplifies treatment by eliminating the need for genotype testing before initiating therapy.
Peso Molecular
883,0000 g/mol
LogP
6,20
TPSA
193,00 Ų
Regra dos 5 de Lipinski
Reprovado
Áreas Terapêuticas
Mecanismo de Ação
Inhibits the NS5A protein of hepatitis C virus, disrupting viral RNA replication and virion assembly.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits the NS5A protein of hepatitis C virus, disrupting viral RNA replication and virion assembly.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
COC[C@H]1C[C@@H](c2nc(-c3ccc4c(c3)COc3cc5c(ccc6nc([C@@H]7CC[C@H](C)N7C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]c65)cc3-4)c[nH]2)N(C(=O)[C@H](NC(=O)OC)c2ccccc2)C1
InChI
InChI=1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)/t27-,28-,38-,39-,41-,42+/m0/s1
Molecular Formula
C49H54N8O8
HBD / HBA
4 / 10
Ligações Rotacionáveis
13
Átomos Pesados
65
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
Velpatasvir is a pan-genotypic NS5A inhibitor that blocks the nonstructural protein 5A of hepatitis C virus (HCV), which is essential for viral RNA replication and virion assembly. It is used in combination with sofosbuvir (Epclusa) or sofosbuvir and voxilaprevir (Vosevi) for the treatment of chronic HCV infection across all six major genotypes. Its pan-genotypic activity simplifies treatment by eliminating the need for genotype testing before initiating therapy.
Inhibits the NS5A protein of hepatitis C virus, disrupting viral RNA replication and virion assembly.
Yes, Velpatasvir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3545062. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 67683363. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="velpatasvir"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/velpatasvir/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/velpatasvir/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/velpatasvir/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="velpatasvir"></drugfyi-drug>